IFNAR2 and hepatocellular carcinoma: The present study is an extension to our previous work (Sakon et al, 2002), in which we examined the clinical effects of the combination therapy of subcutaneous IFN-α and arterial infusion of 5-FU in 55 patients with HCC associated with Vp3 and investigated whether the response to such therapy is influenced by the expression level of IFNAR2.